| Followers | 843 |
| Posts | 123038 |
| Boards Moderated | 9 |
| Alias Born | 09/05/2002 |
Thursday, December 23, 2021 9:54:33 AM
FDA grants EUA for MRK’s Molnupiravir—with_a_major_limitation:
https://www.prnewswire.com/news-releases/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-for-treatment-of-covid-19-in-certain-adults-301450419.html Emphasis added.
The limitation is warranted, IMO, in light of Molnupiravir’s weak efficacy and questionable safety.
https://www.prnewswire.com/news-releases/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-for-treatment-of-covid-19-in-certain-adults-301450419.html
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Merck's molnupiravir for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate.
The limitation is warranted, IMO, in light of Molnupiravir’s weak efficacy and questionable safety.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent MRK News
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/29/2026 05:24:06 PM
- FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) • Business Wire • 05/29/2026 10:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2026 08:15:25 PM
- Merck Congratulates Ontario Government on Expanding Pharmacy Scope to Help Improve Access to Care • PR Newswire (Canada) • 05/28/2026 01:00:00 PM
- Merck félicite le gouvernement de l'Ontario d'avoir élargi le champ d'activité des pharmaciens pour améliorer l'accès aux soins • PR Newswire (Canada) • 05/28/2026 01:00:00 PM
- Merck to Participate in the Jefferies Global Healthcare Conference • Business Wire • 05/28/2026 10:45:00 AM
- Merck Announces Third-Quarter 2026 Dividend • Business Wire • 05/26/2026 05:28:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 08:21:18 PM
- Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer • Business Wire • 05/22/2026 11:55:00 AM
- Synergis Software lance Adept Cloud, une plateforme de gestion de documents d'ingénierie native du nuage conçue pour les industries à forte intensité d'actifs • PR Newswire (Canada) • 05/21/2026 05:42:00 PM
- Synergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries • PR Newswire (US) • 05/21/2026 10:02:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/20/2026 08:23:39 PM
- Synergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries • PR Newswire (Canada) • 05/20/2026 03:02:00 PM
- Synergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries • PR Newswire (US) • 05/20/2026 03:02:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:14:07 PM
- Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer • Business Wire • 05/18/2026 10:45:00 AM
- Form 13F-HR - Quarterly report filed by institutional managers, Holdings • Edgar (US Regulatory) • 05/13/2026 08:06:47 PM
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities • InvestorsHub NewsWire • 05/13/2026 01:00:00 PM
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities • GlobeNewswire Inc. • 05/13/2026 12:30:00 PM
- Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026 • Business Wire • 05/12/2026 10:45:00 AM
- Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate • Business Wire • 05/07/2026 06:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 04:18:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 04:14:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 04:10:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 04:07:01 PM
